Author:
Berger Joseph R.,Fox Robert J.
Publisher
Springer Science and Business Media LLC
Subject
Virology,Cellular and Molecular Neuroscience,Neurology (clinical),Neurology
Reference7 articles.
1. Biogen. TYSABRI (natalizumab): PML Incidence in patients receiving TYSABRI [online]. Available at: http://medinfo.biogen.com . Accessed November 8, 2015.
2. Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870–1880
3. Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B (2014) Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 21:299–304
4. Cutter GR, Stuve O (2014) Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 20:1304–1305
5. Fox RJ, Rudick RA (2012) Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 78:436–437
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献